Awaiting product image

Article: When is ponatinib a suitable treatment option for patients with chronic phase CML and how can we optimize the benefit/risk ratio?

€2.42

SKU: product-article-18763 Category:

Description

When is ponatinib a suitable treatment option for patients with chronic phase CML and how can we optimize the benefit/risk ratio?

Reviews

There are no reviews yet.

Be the first to review “Article: When is ponatinib a suitable treatment option for patients with chronic phase CML and how can we optimize the benefit/risk ratio?”

Your email address will not be published. Required fields are marked *

Related products